← All Entrada Therapeutics, INC filings

Entrada Therapeutics, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
TRDA
Entrada Therapeutics, INC
10-K: Entrada Therapeutics Reports 2025 Losses Amid Clinical Progress
Entrada Therapeutics reports a significant net loss for 2025 despite advancing multiple clinical programs for Duchenne muscular dystrophy and inherited retinal diseases, with cash runway into Q3 2027.
NASDAQ
TRDA
Entrada Therapeutics, INC
10-K: Entrada Therapeutics Reports Progress on DMD Programs, Lifts Clinical Hold on ENTR-601-44
Entrada Therapeutics' 10-K filing highlights advancements in its Duchenne muscular dystrophy (DMD) programs, including the lifting of a clinical hold on ENTR-601-44 and planned clinical trial initiations.
NASDAQ
TRDA
Entrada Therapeutics, INC
10-K: Entrada Therapeutics Secures Key Lease, Advances Pipeline with Vertex Collaboration
Entrada Therapeutics finalizes a significant lease agreement for its headquarters while progressing its pipeline, including a collaboration with Vertex Pharmaceuticals.